Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aziyo Biologics ( (ELUT) ) has shared an announcement.
On October 1, 2025, Elutia Inc. announced the completion of the sale of its BioEnvelope business to Boston Scientific Corporation for $88 million. This strategic divestiture allows Elutia to concentrate on advancing its NXT-41x biomatrix platform, which targets reconstruction infections post-mastectomy. The sale strengthens Elutia’s financial position, enabling the company to fully fund the development and launch of NXT-41x, a product poised to capture a significant share of the $1.5 billion U.S. market for breast reconstruction biologics. The transaction also included a non-competition agreement and transitional support services to ensure a smooth transfer of the CIED Business assets.
The most recent analyst rating on (ELUT) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.
Spark’s Take on ELUT Stock
According to Spark, TipRanks’ AI Analyst, ELUT is a Neutral.
Aziyo Biologics’ overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While the earnings call highlighted some positive developments, the company’s financial instability and valuation concerns weigh heavily on the score.
To see Spark’s full report on ELUT stock, click here.
More about Aziyo Biologics
Elutia Inc. is a company specializing in the development and commercialization of drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients. The company focuses on implantable technologies, particularly in the area of breast reconstruction, with a mission to humanize medicine and enhance patient outcomes.
Average Trading Volume: 142,979
Technical Sentiment Signal: Sell
Current Market Cap: $37.36M
For detailed information about ELUT stock, go to TipRanks’ Stock Analysis page.